Calcitonin Gene-Related Peptide: A Literature Course

Calcitonin gene-related peptide (CGRP) is one of the most heavily studied sensory neuropeptides in neurology, dermatology and vascular biology. This course walks through the published literature in six modules: what the peptide is, how its receptor is described, what individual studies reported, what adverse events appear in print, what pharmacokinetic information exists, and how CGRP-pathway products are regulated. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, symptoms or treatment. Nothing here is a protocol, a recommendation or a claim of benefit.

Module 1 — What Calcitonin Gene-Related Peptide Is and How It Has Been Studied

CGRP is described in the receptor literature as a 37-amino-acid neuropeptide that signals through a specific receptor complex rather than through the classical calcitonin receptor alone (PMID 32809483). It belongs to the calcitonin/CGRP peptide family, whose other members include calcitonin, amylin and adrenomedullin; a 2020 pharmacology paper examined how a PEGylated adrenomedullin analogue activated both CGRP and adrenomedullin receptors, illustrating the pharmacological overlap within this family (PMID 33132326). Two closely related forms, usually labelled α-CGRP and β-CGRP, are discussed in the receptor literature as products of related genes with overlapping receptor activity (PMID 32809483).

Rather than being confined to one organ, CGRP has been localised across many tissues by immunohistochemical and expression studies. Researchers identified substance P- and CGRP-immunoreactive nerve fibres associated with the glands of external auditory canal skin (PMID 28866875). A dermatological study measured CGRP expression in atopic dermatitis and examined its relationship with patient-reported distress (PMID 37676055). In oncology tissue work, investigators compared substance P and CGRP and their receptors in colorectal adenocarcinoma specimens (PMID 39337103). In the head-pain field, trigeminovascular CGRP function was studied in Cacna1a R192Q-mutated knock-in mice, a genetic migraine model (PMID 28792272).

The methods used across this body of work fall into a small number of categories: tissue staining and expression profiling, receptor pharmacology in cell systems, genetically modified rodent models, medicinal-chemistry programmes aimed at receptor blockade, and clinical reviews of drugs that target the pathway. A 2010 review in a mid-life health journal, for example, discussed CGRP in the context of menopause and vasomotor physiology rather than through an interventional trial (PMID 21799630).

Limits of the evidence in Module 1

Definitional and localisation studies describe where a peptide is present, not what it does in a person. The tissue studies cited above were observational and cross-sectional, so they cannot establish that CGRP caused any of the conditions in which it was detected. None of the verified papers in this module tested CGRP as an administered substance in healthy humans.

Module 2 — Mechanism as Described in the Literature

The CGRP receptor is described in review form as a heteromeric complex in which calcitonin receptor-like receptor pairs with receptor activity-modifying protein 1, producing a binding site with selectivity for CGRP and coupling to intracellular second-messenger signalling (PMID 32809483). That same receptor review frames the complex as a drug target, which is the conceptual bridge between basic pharmacology and the antagonist programmes discussed below (PMID 32809483).

Receptor promiscuity within the peptide family is a recurring mechanistic theme. In the 2020 study of PEGylated adrenomedullin, researchers reported that the modified peptide retained the ability to activate CGRP and adrenomedullin receptor subtypes in a receptor-activation assay, which the authors used to discuss how chemical modification changes receptor engagement (PMID 33132326). This matters for interpretation: signals attributed to "CGRP receptors" in one assay may involve neighbouring receptors of the same family.

Blockade as a mechanistic probe

Much of what the literature says about CGRP function comes from blocking it. Medicinal-chemistry work described a series of azepino-indazoles developed as CGRP receptor antagonists, with the paper reporting structure–activity optimisation of the chemical series against the receptor (PMID 33096162). A hospital-pharmacy review summarised CGRP receptor antagonists specifically in the setting of migraine prophylaxis, describing the rationale for targeting the receptor pharmacologically (PMID 29276263). A later clinician-facing review covered CGRP antagonist therapy and migraine as an established therapeutic class (PMID 35648658).

Animal models add a second mechanistic angle. The knock-in mouse study examined trigeminovascular CGRP function in animals carrying the Cacna1a R192Q mutation, linking a channel mutation associated with familial hemiplegic migraine to CGRP-dependent trigeminovascular responses (PMID 28792272). A separate rat study approached CGRP from the vascular side, reporting that a neuropathic pain state that released CGRP was associated with protection against stroke injury in that model (PMID 32051737).

Limits of the evidence in Module 2

Receptor-level mechanism is generated in cell systems and rodents, and the step from a cAMP readout or a mouse vascular response to a human clinical outcome is not established by these papers. Antagonist studies describe what happens when signalling is reduced; they do not describe the effects of giving CGRP. The verified literature here does not include head-to-head mechanistic comparisons of α- and β-CGRP in humans.

Module 3 — Reported Outcomes by Study

The table below organises the verified papers by model, endpoint and what researchers reported. No entry should be read as a promise of benefit; each is a description of one study's scope.

Reading the outcome literature carefully

Two patterns are worth noting. First, the strongest clinical signal in the verified set concerns blocking CGRP, not administering it: both migraine reviews address antagonists and antibodies directed at the pathway (PMID 29276263, PMID 35648658). Second, several papers describe CGRP as potentially protective in other contexts, such as the rat stroke model in which CGRP release accompanied reduced injury (PMID 32051737). The literature therefore does not support a single directional story about CGRP being "good" or "bad"; its reported role depends on the tissue and the model.

Limits of the evidence in Module 3

The set includes narrative reviews, a case-level report, cross-sectional tissue studies and rodent experiments. A case report cannot establish efficacy, correlations in expression studies cannot establish direction of causation, and rodent stroke or trigeminovascular findings may not transfer to humans. None of these papers reported outcomes of exogenous CGRP administration in healthy volunteers.

Module 4 — Calcitonin Gene-Related Peptide Side Effects: What Studies Report

Adverse-event information in the verified literature comes almost entirely from drugs that target the CGRP pathway, not from CGRP given as a peptide. The hospital-pharmacy review of CGRP receptor antagonists for migraine prophylaxis discussed tolerability and safety among the factors shaping the development of the class, including why some early receptor antagonists did not progress through development (PMID 29276263). The later clinician-oriented review of CGRP antagonist therapy and migraines also addressed safety and monitoring considerations alongside efficacy when describing the class in practice (PMID 35648658).

At the single-patient level, the 2024 report on CGRP monoclonal antibodies in writer's cramp and migraine described the clinical course of the case, which is the only tolerability information that design can generate (PMID 38602109). Preclinical papers in the set were not safety studies: the azepino-indazole chemistry paper reported receptor-antagonist development rather than toxicology outcomes (PMID 33096162), and the PEGylated adrenomedullin study reported receptor activation rather than adverse events (PMID 33132326).

Limits of the evidence in Module 4

No paper in the verified list is a dedicated safety trial with event rates for CGRP itself, so this course cannot list frequencies, severities or comparative risks. Reviews summarise other trials rather than generating primary safety data (PMID 29276263, PMID 35648658). Long-term safety of CGRP-pathway blockade, and any safety profile for administered CGRP, are not addressed by these sources.

Module 5 — Pharmacokinetics Where Data Exist

The verified literature contains very little formal pharmacokinetics for CGRP. The closest available data are indirect. In the 2020 study, researchers used PEGylation of adrenomedullin — a strategy commonly applied to peptides to change their disposition — and reported that the PEGylated peptide still activated CGRP and adrenomedullin receptors (PMID 33132326). That study illustrates the principle that chemical modification of a small peptide can be pursued without abolishing receptor activity, but it examined adrenomedullin rather than CGRP itself (PMID 33132326).

On the antagonist side, the azepino-indazole paper described optimisation of a small-molecule chemical series against the CGRP receptor, which is the stage of drug development at which drug-like properties are typically refined (PMID 33096162). Reviews of the clinical class discussed oral receptor antagonists and injectable monoclonal antibodies as distinct approaches to interrupting the pathway, a distinction that implies different dosing routes (PMID 29276263, PMID 35648658).

Limits of the evidence in Module 5

No verified paper reported half-life, clearance, bioavailability, volume of distribution or plasma concentration–time data for CGRP in humans. Because none of these parameters appears in the sources, this course states no numbers for them. Any pharmacokinetic figure circulating elsewhere is outside the evidence reviewed here.

Module 6 — Regulatory Status, Stated Factually

The regulatory picture differs sharply between CGRP the peptide and drugs that block CGRP signalling.

• Approved drug class. Reviews describe CGRP receptor antagonists and CGRP-targeting monoclonal antibodies as therapies used in migraine care, i.e. products that reached clinical use through conventional regulatory pathways (PMID 29276263, PMID 35648658). A 2024 report described CGRP monoclonal antibodies being used clinically in a patient with migraine (PMID 38602109).
• CGRP as a peptide. The verified literature treats CGRP itself as an endogenous signalling molecule and laboratory reagent — used in receptor-activation assays, tissue staining and animal experiments — rather than as an approved medicine (PMID 32809483, PMID 33132326). Synthetic CGRP supplied for laboratory work is generally labelled research use only, meaning it is not intended for diagnostic or therapeutic use in humans.
• Compounding. In the United States, pharmacy compounding of a drug from a bulk substance depends on that substance's regulatory eligibility under the relevant sections of the Federal Food, Drug, and Cosmetic Act; a peptide used as a research reagent is not equivalent to an approved product or to an eligible bulk substance. Regulatory categories also change over time and differ by country.

These are general regulatory facts, not legal advice, and they say nothing about whether any use would be appropriate for an individual.

Limits of the evidence in Module 6

The verified papers are scientific publications, not regulatory documents, so they confirm clinical use of a drug class but not the current approval status, labelling or indication wording of any specific product. Regulatory status must be checked against primary agency sources, which this course does not reproduce.

What the Studies Did Not Test

Across the verified literature, several questions remain unaddressed:

1. Exogenous CGRP in humans. No paper reported outcomes of administering CGRP to healthy people, so no dose, schedule or duration can be stated from these sources.
2. Performance, body composition or longevity endpoints. The studies examined trigeminovascular function (PMID 28792272), stroke injury in rats (PMID 32051737), tissue expression (PMID 37676055, PMID 39337103, PMID 28866875) and migraine pharmacology (PMID 29276263) — not fitness or anti-ageing outcomes.
3. Long-term follow-up. The verified set contains no multi-year safety cohort for CGRP blockade or for CGRP exposure.
4. Special populations. Pregnancy, paediatric and organ-impairment populations were not the subject of any verified paper; the menopause discussion was a narrative review rather than an intervention study (PMID 21799630).
5. Direct comparisons. No verified paper compared CGRP-pathway drugs against one another with matched endpoints, and none compared α-CGRP with β-CGRP clinically.

Read together, the literature describes CGRP as a widely distributed sensory neuropeptide with a well-characterised receptor complex (PMID 32809483) whose blockade became a clinical strategy in migraine (PMID 35648658), while other work reported context-dependent roles in vascular protection, skin, glands and tumour tissue. This page is educational only and is not medical advice; questions about symptoms, medicines or treatment belong with a licensed physician.

References

• Calcitonin Gene-Related Peptide Receptor (2026)
• Calcitonin gene-related peptide and menopause (Journal of Mid-life Health, 2010)
• Calcitonin Gene-Related Peptide Receptor Antagonists for Migraine Prophylaxis (Hospital Pharmacy, 2017)
• Activation of Calcitonin Gene-Related Peptide and Adrenomedullin Receptors by PEGylated Adrenomedullin (Biological & Pharmaceutical Bulletin, 2020)
• Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists (Bioorganic & Medicinal Chemistry Letters, 2021)
• Substance P and Calcitonin Gene-Related Peptide in the Glands of External Auditory Canal Skin (Clinical and Experimental Otorhinolaryngology, 2017)
• Calcitonin gene-related peptide antagonist therapy and migraines (JAAPA, 2022)
• Comparison between Substance P and Calcitonin Gene-Related Peptide and Their Receptors in Colorectal Adenocarcinoma (Journal of Clinical Medicine, 2024)
• Expression of calcitonin gene-related peptide in atopic dermatitis and correlation with distress (Immunopharmacology and Immunotoxicology, 2024)
• Trigeminovascular calcitonin gene-related peptide function in Cacna1a R192Q-mutated knock-in mice (Journal of Cerebral Blood Flow and Metabolism, 2019)
• Neuropathic pain releasing calcitonin gene related peptide protects against stroke in rats (American Journal of Translational Research, 2020)
• Can calcitonin gene-related peptide monoclonal antibodies ameliorate writer's cramp and migraine? (Neuropsychopharmacology Reports, 2024)